CV Sciences (CVSI) Net Cash Flow Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | -62.71% |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | -33.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.71% |
| Dec 31, 2025 | 54.12% |
| Sep 30, 2025 | -188.61% |
| Jun 30, 2025 | 27.11% |
| Mar 31, 2025 | -30.38% |
| Dec 31, 2024 | -22.27% |
| Sep 30, 2024 | 33.62% |
| Jun 30, 2024 | 59.18% |
| Mar 31, 2024 | -37.03% |
| Dec 31, 2023 | 40.39% |
| Sep 30, 2023 | 71.42% |
| Jun 30, 2023 | 26.78% |
| Mar 31, 2023 | 27.06% |
| Dec 31, 2022 | 51.51% |
| Sep 30, 2022 | 26.34% |
| Jun 30, 2022 | -38.06% |
| Mar 31, 2022 | 14.81% |
| Dec 31, 2021 | -29.03% |
| Sep 30, 2021 | -32.84% |
| Jun 30, 2021 | -41.10% |